An observational study in Hemorrhagic Shock and Traumatic Brain Injury, sponsored by University of Pittsburgh. Completed at 1 site in United States. Open to participants aged 15 Years to 90 Years. Per ClinicalTrials.gov, last updated 2024-02-08.
Sponsored by University of Pittsburgh · Observational
Among 35 studies in Shock, Hemorrhagic with a site in United States — 5 open to participants now, 6 under way, 2 of them phase 3. Shock, Hemorrhagic · United States.
Among the 35 studies in Shock, Hemorrhagic with a site in United States, this one is one of 2 that started in 2018, is one of 9 observational ones, and was the 21st registered.
79 studies on the registry are indexed under Shock, Hemorrhagic; 15 are open to participants now.
This study's enrollment of 1,051 is above the median of 113 across 30 observational studies indexed under Shock, Hemorrhagic.
Browse Shock, Hemorrhagic studies →5 of the 35 studies in Shock, Hemorrhagic with a site in United States are open now, in 1 country. Each count lists the studies.
Of the 9 Shock, Hemorrhagic studies recruiting now, 7 (78%) set no upper age limit and 1 (11%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.
This study: 15 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →35 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 2 started in 2018.
Median enrollment 114 across the 25 interventional studies, 119 across the 9 observational. Of the 23 that completed or were terminated, 12 (52%) have results posted.
5 of 35 have an industry lead sponsor. The 10 most frequent:
University of Pittsburgh is the lead sponsor of 1,419 studies on the registry; 168 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 4 (44%) have results posted.
University of Pittsburgh has 1 study filed under Shock, Hemorrhagic — fewer than ten, so there is no comparison to draw.
1 of the studies in Shock, Hemorrhagic with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05958342Jason SperryCAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial | 2027-03 |
Among the 35 studies in Shock, Hemorrhagic with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
The LITES Network is an operational trauma center consortium which has the expertise, track record and confirmed capabilities to conduct prospective, multicenter, injury care and outcomes research of relevance to the Department of Defense (DoD).
Hemorrhage and Traumatic Brain Injury (TBI) are responsible for the largest proportion of all trauma-related deaths. It is the poly-trauma patient who suffers both hemorrhagic shock and traumatic brain injury where a paucity of evidence exists to direct treatment, limiting the development of beneficial trauma practice guidelines.
The use of Whole Blood (WB) for early trauma resuscitation has been touted as the 'essential next step' in the evolution of trauma resuscitation. Despite its historical and more recent use, little is known regarding WB's benefit relative to the 'current practice' ratio-based blood component therapy in the acutely bleeding patient, and even less is known regarding its effects in patients with TBI.
AIM#1: Evaluate patient centered outcomes associated with early whole blood resuscitation practice as compared to component resuscitation in poly-trauma patients with hemorrhagic shock and further characterize outcome benefits in those with traumatic brain injury.
AIM#2: Characterize blood pressure and resuscitation endpoints during the acute resuscitation phase of care and the associated/attributable outcomes for traumatic brain injury in patients with hemorrhagic shock.
General Hypothesis #1: Whole blood resuscitation will be associated with improved mortality and resuscitation outcomes in poly-trauma patients and long term neurological outcome in those patients with traumatic brain injury as compared to those resuscitated with component therapy.
General Hypothesis #2: Differences in prehospital and acute phase resuscitation systolic blood pressure will be associated with differential outcomes in patients with traumatic brain injury at discharge and at 6 months.
Study Design: The LITES network will perform a multicenter, prospective, observational cohort study over a 4 year period to determine the impact of whole blood resuscitation in trauma patients with hemorrhagic shock at risk of large volume resuscitation with and without TBI. Early whole blood resuscitation will be compared to standard component resuscitation. The study will also further characterize blood pressure and resuscitation endpoints in poly-trauma patients with traumatic brain injury. Six Trauma sites with appropriate characteristics will be selected from 12 LITES Network sites across the country.
Study Setting: The study will be performed utilizing busy level I trauma centers within the LITES Network located across the country, at sites where either whole blood has currently been incorporated into standard of care or where component blood transfusion is being utilized for patients in hemorrhagic shock at risk for large volume resuscitation.
Study Population: The study will focus on patients who suffer blunt or penetrating injury, transported to a SWAT participating LITES trauma center with evidence of hemorrhagic shock at risk of large volume blood resuscitation.
Background
The LITES Network is an operational trauma center consortium which has the expertise, track record and confirmed capabilities to conduct prospective, multicenter, injury care and outcomes research of relevance to the Department of Defense (DoD). Clinical trials from the point of injury in the prehospital arena through the trauma bay and operating theatre, thru ICU and beyond discharge are feasible and critical to the overall goals of the network. Novel capabilities include prehospital point of care testing for shock severity and sequential coagulopathy measurements. The network and leadership have a track record of Exception From Informed Consent (EFIC) trials and expertise with those injury subtypes including traumatic brain injury, hemorrhagic shock and coagulopathy of trauma, poly-trauma and severe extremity trauma. In addition to the track record and proven capabilities, the LITES Network uses a central IRB and efficient methods to minimize time, resources, cost and regulatory burdens and improve recruitment, consent rates and ease of data acquisition to promote successful execution of those task orders provided to the network from the DoD.
Traumatic injury represents an incredible health care burden in the United States and worldwide.1 Hemorrhage and Traumatic Brain Injury (TBI) are responsible for the largest proportion of all trauma-related deaths. Despite advances in trauma resuscitation and brain injury management, few therapeutic interventions are available to reduce the downstream morbidity and mortality attributable to these injury patterns. It is the poly-trauma patient who suffers both hemorrhagic shock and traumatic brain injury where a paucity of evidence exists to direct treatment, limiting the development of beneficial trauma practice guidelines.
Ongoing traumatic blood loss is complicated by trauma induced coagulopathy which results in further unbridled hemorrhage and resultant shock and organ dysfunction. Secondary to increasing evidence and knowledge, in-hospital resuscitation of traumatic hemorrhage has changed over the past decade to reduce the coagulopathic response to ischemia and tissue injury. The underlying principle of current resuscitation practice focuses on preventing or reversing the effects of coagulopathy with the early use of a balanced component transfusion strategy (1:1:1 - plasma: packed red blood cells: platelets). This reconstituted strategy has also been coined 'whole blood-like' resuscitation despite being inferior from a compositional standpoint relative to Whole Blood (WB). The use of WB was historically the gold standard for treating hemorrhagic shock during World War I and II, prior to sweeping changes in blood banking practice. The use of WB for early trauma resuscitation is making a resurgence, primarily based upon the military experience and has been touted as the 'essential next step' in the evolution of trauma resuscitation. Despite its historical and more recent use, little is known regarding WB's benefit relative to the 'current practice' ratio based blood component therapy in the acutely injured patients and even less is known regarding its effects in patients with TBI.
Permissive hypotension has been thought to improve outcome in injured patients with hemorrhagic shock in the prehospital and acute resuscitation phase of treatment allowing for the ability to obtain surgical control of bleeding while minimizing ongoing hemorrhage. Despite this benefit for hemorrhagic shock patients, hypotension has been consistently shown to be associated with worse outcomes in patients with TBI. Interestingly, newer animal data suggests permissive hypotension may be beneficial in a swine TBI model.The majority of prior, high level TBI trials have excluded patients with concomitant hemorrhagic shock. Prospective evidence and long term TBI outcome data are lacking for these complex poly-trauma patients and the most appropriate blood pressure and most efficacious resuscitation target for patients with TBI and acute hemorrhage remain poorly characterized.
Hypothesis #1A: Whole blood resuscitation will be associated with a lower 4 hour mortality in poly-trauma patients as compared to those resuscitated with component therapy.
Hypothesis #1B: Whole blood resuscitation will be associated with a lower incidence of 12 hour and 24 hour mortality, a lower incidence of death from exsanguination, incidence of MOF, nosocomial infection, improved transfusion ratios, lower overall blood transfusion requirements and shorter time to hemostasis as compared to those resuscitated with component therapy.
Hypothesis #1C: Whole blood resuscitation will be associated with an improved Glasgow Outcome Score-Extended at 6 months post injury as compared to those resuscitated with component therapy in patients with traumatic brain injury.
Hypothesis #2A: A nadir prehospital and acute phase resuscitation systolic blood pressure greater than or equal to 120 mmHg will be associated with improved traumatic brain injury outcomes at discharge and at 6 months.
Hypothesis #2B: The magnitude of the dose depth curve of systolic blood pressure during the prehospital and acute phase resuscitation will be associated with neurological outcome differences at discharge and at 6 months following traumatic brain injury.
Research Design and Methods
Study Design: The LITES Network will perform a multicenter, prospective, observational cohort study over a 4 year period to determine the impact of whole blood resuscitation in trauma patients with hemorrhagic shock at risk of large volume resuscitation with and without TBI. Early whole blood resuscitation will be compared to standard component resuscitation. The study will also further characterize blood pressure and resuscitation endpoints in poly-trauma patients with traumatic brain injury. Six trauma sites with appropriate characteristics will be selected from 12 network sites across the country.
Study Setting: The study will be performed utilizing busy level I trauma centers from within the LITES Network located across the country, at sites where either whole blood has currently been incorporated into standard of care or where component blood transfusion is being utilized for patients in hemorrhagic shock at risk for large volume resuscitation. Due to the paucity of trauma centers who are currently utilizing whole blood for trauma patients as standard of care, the potential to incorporate sites outside of the current LITES Network may be required over time.
The study will focus on patients who suffer blunt or penetrating injury, transported to a SWAT participating LITES trauma center with evidence of hemorrhagic shock at risk of large volume resuscitation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with blunt or penetrating injury who meet the following criteria: 1, 2, and 3
Has 2 or more of any of the following:
AND
Taken to the Operating Room (laparotomy, thoracotomy or vascular exploration) or Interventional Radiology within 60 minutes of arrival.
AND
Exclusion Criteria:
Subjects at enrolling centers that utilize whole blood for hemorrhagic shock
Subjects at enrolling centers that utilize component therapy for hemorrhagic shock
4 Hour Mortality
mortality at 4 hours
Time frame: 4 hours
24 Hour Mortality
mortality at 24 hours
Time frame: 24 hours
| Milestone | Whole Blood | Component Therapy |
|---|---|---|
| Started | 624 | 427 |
| Completed | 624 | 427 |
| Not completed | 0 | 0 |
mortality at 4 hours
| Participants | Whole Blood | Component Therapy |
|---|---|---|
| 4 Hour Mortality | 50 | 32 |
mortality at 24 hours
| Participants | Whole Blood | Component Therapy |
|---|---|---|
| 24 Hour Mortality | 82 | 49 |
Collected over 28 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Whole Blood | 110/624 (17.6%) | 87/624 (13.9%) | 0/624 (0%) |
| Component Therapy | 66/427 (15.5%) | 48/427 (11.2%) | 0/427 (0%) |
| Event | Whole Blood | Component Therapy |
|---|---|---|
| Deep Vein ThrombosisBlood and lymphatic system disorders | 49/624 | 22/427 |
| Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders | 38/624 | 26/427 |
| Age, Continuous(years) | Whole Blood | Component Therapy | Total |
|---|---|---|---|
| Median | 35.0 (26.0 to 51.0) | 35.0 (25.0 to 47.0) | 35.0 (26.0 to 49.0) |
| Sex: Female, Male(Participants) | Whole Blood | Component Therapy | Total |
|---|---|---|---|
| Female | 78 | 130 | 208 |
| Male | 546 | 297 | 843 |
| Race (NIH/OMB)(Participants) | Whole Blood | Component Therapy | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 225 | 139 | 364 |
| White | 280 | 235 | 515 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 119 | 53 | 172 |
| Region of Enrollment(participants) | Whole Blood | Component Therapy | Total |
|---|---|---|---|
| United States | 624 | 427 | 1051 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2018 to primary completion in Sep 2021, 40 months.
Results were first posted in Feb 2024, 2 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.